Mortality risk assessment and the role of thrombolysis in pulmonary embolism

Clinics in Chest Medicine

Volumn 31, Issue 4, 2010, Pages 759-769

  Lankeit, Mareike ^a   Konstantinides, Stavros ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Mortality risk; Pulmonary embolism; Risk assessment; Thrombolysis

Indexed keywords

ALTEPLASE; FATTY ACID BINDING PROTEIN; GROWTH DIFFERENTIATION FACTOR 15; HEPARIN; RETEPLASE; STREPTOKINASE; TENECTEPLASE; TROPONIN I; TROPONIN T; UROKINASE;

ACUTE DISEASE; BLOOD CLOT LYSIS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DISEASE SEVERITY; DRUG EFFICACY; ECHOCARDIOGRAPHY; HEART MUSCLE INJURY; HEART RIGHT VENTRICLE FAILURE; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; LUNG ANGIOGRAPHY; LUNG EMBOLISM; MORTALITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT CONTRAINDICATION;

BIOLOGICAL MARKERS; CARDIOMYOPATHIES; FIBRINOLYTIC AGENTS; HUMANS; PULMONARY EMBOLISM; RISK ASSESSMENT; THROMBOLYTIC THERAPY; TROPONIN;

EID: 78049486946     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2010.06.007     Document Type: Review

References (96)

1. Silverstein M.D., Heit J.A., Mohr D.N., et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998, 158(6):585-593.
2. Anderson F.A., Wheeler H.B., Goldberg R.J., et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991, 151(5):933-938.
3. White R.H. The epidemiology of venous thromboembolism. Circulation 2003, 107(23 Suppl. 1):I4-I8.
4. Goldhaber S.Z., Visani L., De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999, 353(9162):1386-1389.
5. Kasper W., Konstantinides S., Geibel A., et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997, 30(5):1165-1171.
6. British Thoracic Society Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 1992, 340(8824):873-876.
7. Carson J.L., Kelley M.A., Duff A., et al. The clinical course of pulmonary embolism. N Engl J Med 1992, 326(19):1240-1245.
8. Aujesky D., Jimenez D., Mor M.K., et al. Weekend versus weekday admission and mortality after acute pulmonary embolism. Circulation 2009, 119(7):962-968.
9. Laporte S., Mismetti P., Decousus H., et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 2008, 117(13):1711-1716.
10. Internet Communication. Available at:. Accessed June 23, 2010. http://www.surgeongeneral.gov/news/pressreleases/pr20080915.html.
11. Cohen A.T., Agnelli G., Anderson F.A., et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007, 98(4):756-764.
12. Cohen A.T., Edmondson R.A., Phillips M.J., et al. The changing pattern of venous thromboembolic disease. Haemostasis 1996, 26(2):65-71.
13. Lindblad B., Sternby N.H., Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991, 302(6778):709-711.
14. Kasper W., Konstantinides S., Geibel A., et al. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997, 77(4):346-349.
15. Konstantinides S. Pulmonary embolism: impact of right ventricular dysfunction. Curr Opin Cardiol 2005, 20(6):496-501.
16. Miller R.L., Das S., Anandarangam T., et al. Association between right ventricular function and perfusion abnormalities in hemodynamically stable patients with acute pulmonary embolism. Chest 1998, 113(3):665-670.
17. McIntyre K.M., Sasahara A.A. Determinants of right ventricular function and hemodynamics after pulmonary embolism. Chest 1974, 65(5):534-543.
18. McIntyre K.M., Sasahara A.A. The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease. Am J Cardiol 1971, 28(3):288-294.
19. Greyson C., Xu Y., Cohen J., et al. Right ventricular dysfunction persists following brief right ventricular pressure overload. Cardiovasc Res 1997, 34(2):281-288.
20. Schmitto J.D., Doerge H., Post H., et al. Progressive right ventricular failure is not explained by myocardial ischemia in a pig model of right ventricular pressure overload. Eur J Cardiothorac Surg 2009, 35(2):229-234.
21. Chung T., Connor D., Joseph J., et al. Platelet activation in acute pulmonary embolism. J Thromb Haemost 2007, 5(5):918-924.
22. Smulders Y.M. Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction. Cardiovasc Res 2000, 48(1):23-33.
23. Konstantinides S., Geibel A., Kasper W., et al. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. Circulation 1998, 97(19):1946-1951.
24. Konstantinides S. Clinical practice. Acute pulmonary embolism. N Engl J Med 2008, 359(26):2804-2813.
25. Torbicki A., Perrier A., Konstantinides S.V., et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008, 29:2276-2315.
26. Kucher N., Rossi E., De Rosa M., et al. Massive pulmonary embolism. Circulation 2006, 113(4):577-582.
27. Stein P.D., Henry J.W. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995, 108(4):978-981.
28. Grifoni S., Olivotto I., Cecchini P., et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000, 101(24):2817-2822.
29. Righini M., Le Gal G., Aujesky D., et al. Diagnosis of pulmonary embolism by multidetector CT alone or combined with venous ultrasonography of the leg: a randomised non-inferiority trial. Lancet 2008, 371(9621):1343-1352.
30. Stein P.D., Fowler S.E., Goodman L.R., et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med 2006, 354(22):2317-2327.
31. van Belle A., Buller H.R., Huisman M.V., et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 2006, 295(2):172-179.
32. Torbicki A., Galie N., Covezzoli A., et al. Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol 2003, 41(12):2245-2251.
33. Eid-Lidt G., Gaspar J., Sandoval J., et al. Combined clot fragmentation and aspiration in patients with acute pulmonary embolism. Chest 2008, 134(1):54-60.
34. Kucher N., Goldhaber S.Z. Mechanical catheter intervention in massive pulmonary embolism: proof of concept. Chest 2008, 134(1):2-4.
35. Kearon C., Kahn S.R., Agnelli G., et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133(Suppl 6):454S-545.
36. Miller G.A., Sutton G.C., Kerr I.H., et al. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Heart J 1971, 33(4):616.
37. The urokinase pulmonary embolism trial. A national cooperative study. Circulation 1973, 47(Suppl 2):II1-108.
38. Tibbutt D.A., Davies J.A., Anderson J.A., et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. Br Med J 1974, 1(904):343-347.
39. Ly B., Arnesen H., Eie H., et al. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 1978, 203(6):465-470.
40. Marini C., Di Ricco G., Rossi G., et al. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration 1988, 54(3):162-173.
41. Levine M., Hirsh J., Weitz J., et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990, 98(6):1473-1479.
42. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. Chest 1990, 97(3):528-533.
43. Dalla-Volta S., Palla A., Santolicandro A., et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol 1992, 20(3):520-526.
44. Goldhaber S.Z., Haire W.D., Feldstein M.L., et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993, 341(8844):507-511.
45. Dalen J.E., Banas J.S., Brooks H.L., et al. Resolution rate of acute pulmonary embolism in man. N Engl J Med 1969, 280(22):1194-1199.
46. Konstantinides S., Tiede N., Geibel A., et al. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol 1998, 82(8):966-970.
47. Konstantinides S., Geibel A., Heusel G., et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002, 347(15):1143-1150.
48. Kanter D.S., Mikkola K.M., Patel S.R., et al. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest 1997, 111(5):1241-1245.
49. Sors H., Pacouret G., Azarian R., et al. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest 1994, 106(3):712-717.
50. Goldhaber S.Z., Kessler C.M., Heit J.A., et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol 1992, 20(1):24-30.
51. Meyer G., Sors H., Charbonnier B., et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. J Am Coll Cardiol 1992, 19(2):239-245.
52. Goldhaber S.Z., Kessler C.M., Heit J., et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988, 2(8606):293-298.
53. Verstraete M., Miller G.A., Bounameaux H., et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988, 77(2):353-360.
54. Urokinase-streptokinase embolism trial. Phase 2 results. A cooperative study. JAMA 1974, 229(12):1606-1613.
55. Konstantinides S., Marder V.J. Thrombolysis in venous thromboembolism. Hemostasis and thrombosis 2006, 1317-1329. Lippincott Williams and Wilkins, Philadelphia. R.W. Colman, V.J. Marder, A.W. Clowes (Eds.).
56. Hamel E., Pacouret G., Vincentelli D., et al. Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation: results from a 128-patient monocenter registry. Chest 2001, 120(1):120-125.
57. Meyer G., Gisselbrecht M., Diehl J.L., et al. Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism. Am J Med 1998, 105(6):472-477.
58. Wan S., Quinlan D.J., Agnelli G., et al. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004, 110(6):744-749.
59. Meneveau N., Seronde M.F., Blonde M.C., et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest 2006, 129(4):1043-1050.
60. Daniels L.B., Parker J.A., Patel S.R., et al. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol 1997, 80(2):184-188.
61. Rose P.S., Punjabi N.M., Pearse D.B. Treatment of right heart thromboemboli. Chest 2002, 121(3):806-814.
62. Chartier L., Bera J., Delomez M., et al. Free-floating thrombi in the right heart: diagnosis, management, and prognostic indexes in 38 consecutive patients. Circulation 1999, 99(21):2779-2783.
63. Meneveau N., Schiele F., Metz D., et al. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol 1998, 31(5):1057-1063.
64. Meneveau N., Schiele F., Vuillemenot A., et al. Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. Eur Heart J 1997, 18(7):1141-1148.
65. Goldhaber S.Z., Agnelli G., Levine M.N. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. Chest 1994, 106(3):718-724.
66. Tebbe U., Graf A., Kamke W., et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J 1999, 138(1 Pt 1):39-44.
67. Becattini C., Agnelli G., Salvi A., et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res 2010, 125(3):e82-e86.
68. Kucher N., Goldhaber S.Z. Management of massive pulmonary embolism. Circulation 2005, 112(2):e28-32.
69. Ribeiro A., Lindmarker P., Juhlin-Dannfelt A., et al. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J 1997, 134(3):479-487.
70. Kucher N., Rossi E., De Rosa M., et al. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med 2005, 165(15):1777-1781.
71. ten Wolde M., Sohne M., Quak E., et al. Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med 2004, 164(15):1685-1689.
72. Sanchez O., Trinquart L., Colombet I., et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J 2008, 29(12):1569-1577.
73. Binder L., Pieske B., Olschewski M., et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 2005, 112(11):1573-1579.
74. Scridon T., Scridon C., Skali H., et al. Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism. Am J Cardiol 2005, 96(2):303-305.
75. Kucher N., Wallmann D., Carone A., et al. Incremental prognostic value of troponin I and echocardiography in patients with acute pulmonary embolism. Eur Heart J 2003, 24(18):1651-1656.
76. Schoepf U.J., Kucher N., Kipfmueller F., et al. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation 2004, 110(20):3276-3280.
77. Kucher N., Printzen G., Doernhoefer T., et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003, 107(12):1576-1578.
78. Kucher N., Printzen G., Goldhaber S.Z. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003, 107(20):2545-2547.
79. Pruszczyk P., Kostrubiec M., Bochowicz A., et al. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J 2003, 22(4):649-653.
80. ten Wolde M., Tulevski, Mulder J.W., et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 2003, 107(16):2082-2084.
81. Kucher N., Goldhaber S.Z. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation 2003, 108(18):2191-2194.
82. Giannitsis E., Katus H.A. Risk stratification in pulmonary embolism based on biomarkers and echocardiography. Circulation 2005, 112(11):1520-1521.
83. Klok F.A., Mos I.C., Huisman M.V. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008, 178(4):425-430.
84. Sanchez O., Trinquart L., Caille V., et al. Prognostic factors for pulmonary embolism: the PREP study, a prospective multicenter cohort study. Am J Respir Crit Care Med 2010, 181(2):168-173.
85. Korff S., Katus H.A., Giannitsis E. Differential diagnosis of elevated troponins. Heart 2006, 92(7):987-993.
86. Becattini C., Vedovati M.C., Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007, 116(4):427-433.
87. Jimenez D., Uresandi F., Otero R., et al. Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and metaanalysis. Chest 2009, 136(4):974-982.
88. Lankeit M., Konstantinides S. Tenecteplase can be given to patients with intermediate-risk pulmonary embolism-but should it?. Thromb Res 2009, [Epub ahead of print].
89. Storch J., Thumser A.E. The fatty acid transport function of fatty acid-binding proteins. Biochim Biophys Acta 2000, 1486(1):28-44.
90. Alhadi H.A., Fox K.A. Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein. QJM 2004, 97(4):187-198.
91. Pelsers M.M., Hermens W.T., Glatz J.F. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005, 352(1-2):15-35.
92. Puls M., Dellas C., Lankeit M., et al. Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. Eur Heart J 2007, 28(2):224-229.
93. Kaczynska A., Pelsers M.M., Bochowicz A., et al. Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism. Clin Chim Acta 2006, 371(1-2):117-123.
94. Dellas C, Puls M, Lankeit M, et al. Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. J Am Coll Cardiol 2010;55(19):2150-7.
95. Lankeit M., Kempf T., Dellas C., et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 2008, 177(9):1018-1025.
96. Lankeit M., Konstantinides S. Thrombolysis for hemodynamically stable patients with pulmonary embolism: still searching for the intermediate-risk group. Thromb Res 2009, 124(6):647-648.